Is Whole Blood Better for Trauma? New Trial Results

Is Whole Blood Better for Trauma? New Trial Results

Prehospital whole blood resuscitation has long been debated as a potentially superior method for managing traumatic hemorrhage in the field. Consequently, many emergency medical services have integrated whole blood into their protocols despite limited high-level evidence. A recent Phase 3 multicenter trial, known as the TOWAR study, recently investigated this comparison. The findings provide critical clarity for clinicians managing patients in hemorrhagic shock before hospital arrival.

The TOWAR Trial Results and Mortality Rates

Specifically, the researchers assigned 44 air medical bases to provide either whole blood or traditional component therapy. These bases transported over 1,000 eligible patients during the study period. Interestingly, the results showed that 30-day mortality reached 25.9% in the whole-blood group compared to 20.5% in the component group. Furthermore, the adjusted odds ratio did not reach statistical significance. Therefore, the use of whole blood did not result in lower mortality rates compared to red cells and plasma.

Additionally, the trial included an observational substudy focused on the storage age of the blood products. Clinicians often worry that older blood might lose its efficacy over time. However, this study found no significant survival difference between blood stored for 1 to 14 days and blood stored for 15 to 21 days. Similarly, the safety profile remained consistent across both groups. Notably, the researchers observed no substantial differences in adverse events between the two transfusion strategies.

Practical Implications for Prehospital Whole Blood Resuscitation

Although whole blood did not prove superior in survival, it offers distinct logistical advantages. For instance, storing a single product is often easier than managing multiple components like plasma and platelets separately. Similarly, administering one unit of whole blood is faster than sequential component transfusions in high-pressure environments. Consequently, medical directors may still choose whole blood for its operational simplicity rather than its clinical superiority.

Ultimately, this evidence suggests that both whole blood and component therapy are effective for prehospital resuscitation. Thus, trauma systems should decide based on their local logistical capabilities and supply chains. While the TOWAR trial clarifies survival outcomes, it also reaffirms the safety of both approaches for critically injured patients.

Frequently Asked Questions

Q1: Did whole blood resuscitation reduce 30-day mortality in the study?

No, the trial found that 30-day mortality was 25.9% in the whole-blood group compared to 20.5% in the component group, which was not a statistically significant reduction.

Q2: Does the storage age of whole blood affect patient outcomes?

The observational substudy found no significant difference in 30-day mortality based on storage age, indicating that whole blood stored for up to 21 days remains clinically effective.

References

1. Sperry JL et al. Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage. N Engl J Med. 2026 May 18. doi: 10.1056/NEJMoa2602167. PMID: 42150044.
2. Green L et al. Pre-hospital Transfusion of Whole Blood in Traumatic Haemorrhage (SWiFT): a Multicentre, Open-label, Randomised Controlled Trial. N Engl J Med. 2026 Mar 17.
3. Brown JB et al. Prehospital Trauma Compendium: Transfusion of Blood Products in Trauma. Prehosp Emerg Care. 2025 Apr 1.